Work

Evaluation of anticancer therapy- related dermatologic adverse events: insights from fda's faers dataset

Year: 2024

Type: article

Abstract: melanocytes with large pleomorphic nuclei and abundant cytoplasm, associated with common acquired nevus at its periphery.The tumor was positive on Melan-A, negative for PRAME and showed a low proliferative index of less than 5% on Ki-67 stain.p16 expression was preserved.BRAF V600E staining was positive in both populations while BAP1 expression was lost in the large epithelioid melanocytes.Both lesions were diagnosed as BAP1-inactivated low grade melanocytomas. Conclusions:The occurrence of a single BIMT can be a sporadic event, but the presence of two BAP-1 inactivated melanocytomas raises the possibility of a germline BAP1 mutation and BAP1-TPDS should be considered clinically.Diagnosis is established with detection of loss-of-function germline BAP1 mutation.There are no evidence-based guidelines on the optimal management of BIMTs.Affected patients have an increased susceptibility to other cutaneous and solid-organ malignancies, hence cancer surveillance with annual dermatologic and ophthalmological reviews, urinalysis, and appropriate abdominal imaging is required.

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2024.100199

Authors: S. Salah, D. Kerob, C. Pages Laurent, M. Lacouture, V. Sibaud

Institutions: Roche (France), Institut universitaire du cancer de Toulouse Oncopole, New York University

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,200